Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Prior ASCT Has a Negative Impact on Outcomes in Relapsed/Refractory Multiple Myeloma Patients after BCMA CAR-T Therapy

Chunxiang Jin, Rongrong Chen, Shan Fu, Alex H. Chang, He Huang, Yongxian Hu

Blood (2024) 144 (Supplement 1): 7082.

https://doi.org/10.1182/blood-2024-201470

Published: 2024

Journal Articles

APRIL CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial

Wenxiao Li, Yongxian Hu, Mingming Zhang, Xinyi Lai, Mengyu Zhao, Shan Fu, Ruimin Hong, Alex H. Chang, He Huang

Blood (2024) 144 (Supplement 1): 7229.

https://doi.org/10.1182/blood-2024-209660

Published: 2024

Journal Articles

1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust in vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Yongxian Hu, Mingming Zhang, Shan Fu, Ruimin Hong, Jiazhen Cui, Simao Huang, Min Gao, Daojun Bai, Jingjing Ren, Xingbing Wang, Yugang Guo, Li Tang, He Huang

Blood (2024) 144 (Supplement 1): 2074.

https://doi.org/10.1182/blood-2024-207694

Published: 2024

Journal Articles

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

Blood (2024) 144 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2024-209418

Published: 2024

Journal Articles

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2 ) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

Mingming Zhang, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Chang, He Huang

Blood (2024) 144 (Supplement 1): 91.

https://doi.org/10.1182/blood-2024-210462

Published: 2024

Journal Articles

A Single-Cell Transcriptomic Atlas of Cytokine Storm in CAR-T Therapy, COVID-19, and SLE

Xia Li, Haikun Lin, Boxiang Wu, Xinyi Lai, Yinnan Tong, Jinyan Huang, Pengxu Qian, Yongxian Hu, He Huang

Blood (2024) 144 (Supplement 1): 420.

https://doi.org/10.1182/blood-2024-201300

Published: 2024

Journal Articles

IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies

Yugang Guo, Qianwen Xu, Lei Xue, Erlin Chen, Xuhan Zhang, Chonglin Liu, Min Gao, Youjia Li, Jingjing Ren, Karthik Sathiyanadan, Li Tang, He Huang, Yongxian Hu, Xingbing Wang

Blood (2024) 144 (Supplement 1): 92.

https://doi.org/10.1182/blood-2024-206439

Published: 2024

Journal Articles

Targeting Mitophagy Enhances Cytotoxicity of Autologously-Derived CAR-T Cells

Rongrong Chen, Mingming Zhang, Xufeng Cen, Chunxiang Jin, Yi Luo, Hongguang Xia, Rongqing Pan, He Huang, Yongxian Hu

Blood (2024) 144 (Supplement 1): 7137.

https://doi.org/10.1182/blood-2024-203326

Published: 2024

Journal Articles

Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL

Lichao Liu, Ruihao Huang, Yongxian Hu, Sanfang Tu, Na Wang, Hai Yi, Qiuying Gao, Jian Zhou, Xiaoqi Wang, Cheng Zhang, Xi Zhang

Blood (2024) 144 (Supplement 1): 3469.

https://doi.org/10.1182/blood-2024-207676

Published: 2024

Journal Articles

A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial

Yongxian Hu, Yali Zhou, Mingming Zhang, Shan Fu, Yong Yu, Ming Gao, Ruimin Hong, Houli Zhao, Lu Han, Jiangtao Ren, He Huang

Blood (2024) 144 (Supplement 1): 921.

https://doi.org/10.1182/blood-2024-207322

Published: 2024

Journal Articles

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Tingting Yang, Yetian Dong, Mingming Zhang, Jingjing Feng, Shan Fu, Pingnan Xiao, Ruimin Hong, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu

Blood (2024) 144 (Supplement 1): 2818.

https://doi.org/10.1182/blood-2024-210124

Published: 2024

Journal Articles

CD19 CAR-T Therapy for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia: A Multicenter Study

Jinglei Yu, Fengmei Song, Mingming Zhang, Mingfeng Zhao, Wei Sang, Songfu Jiang, Lixin Wang, Xingbing Wang, He Huang, Yongxian Hu, Guoqing Wei

Blood (2024) 144 (Supplement 1): 4201.

https://doi.org/10.1182/blood-2024-210616

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of BCMA-Targeted CAR-T Cell Recipients with Coronavirus Disease 2019 during the Omicron Wave: A Retrospective Study

Haiqiong Zheng, Shi Han, Houli Zhao, Yongxian Hu, He Huang

Blood (2024) 144 (Supplement 1): 5170.1.

https://doi.org/10.1182/blood-2024-207233

Published: 2024

Journal Articles

Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma

Biao Zheng, Yongxian Hu, Jiqin Zhang, Mingming Zhang, Wei Li, Wenjun Wu, Jiazhen Cui, Guoqing Wei, Bing Du, Mingyao Liu, He Huang

Blood (2023) 142 (Supplement 1): 2108.

https://doi.org/10.1182/blood-2023-185573

Published: 2023

Journal Articles

Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

Mingming Zhang, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Chang, He Huang

Blood (2023) 142 (Supplement 1): 891.

https://doi.org/10.1182/blood-2023-186225

Published: 2023

Journal Articles

Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL

Yongxian HU, Guoqing Wei, Shan Fu, Pingnan Xiao, Jingjing Feng, Mingming Zhang, Xingbing Wang, Dongrui Wang, Jun Li, He Huang

Blood (2023) 142 (Supplement 1): 2111.

https://doi.org/10.1182/blood-2023-189052

Published: 2023

Journal Articles

CD19/BCMA CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus - Safety and Preliminary Efficacy Data from a Phase I Clinical Study

Jingjing Feng, Yongxian HU, Alex H. Chang, He Huang

Blood (2023) 142 (Supplement 1): 4835.

https://doi.org/10.1182/blood-2023-186669

Published: 2023

Journal Articles

A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy

Blood (2023) 142 (Supplement 1): 101.

https://doi.org/10.1182/blood-2023-185236

Published: 2023

Journal Articles

A Multicenter Study of CAR-T Cell Therapy for Relapse of B-ALL Post Allogeneic Stem Cell Transplantation

Jingjing Feng, He Huang, Yongxian HU

Blood (2023) 142 (Supplement 1): 3485.

https://doi.org/10.1182/blood-2023-184740

Published: 2023

Journal Articles

Characteristics of Central Nervous System Relapse after CD19 CAR-T Cell Therapy in R/R NHL

Mengyu Zhao, Tingting Yang, Yetian Dong, Wenxiao Li, Tianning Gu, Linghui Zhou, Jiazhen Cui, Wenfa Huang, Mingming Zhang, Lei Wang, Lixin Wang, Delin Kong, He Huang, Yongxian HU

Blood (2023) 142 (Supplement 1): 6915.

https://doi.org/10.1182/blood-2023-187951

Published: 2023

NARROW

Prior ASCT Has a Negative Impact on Outcomes in Relapsed/Refractory Multiple Myeloma Patients after BCMA CAR-T Therapy

APRIL CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial

1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust in vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2 ) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

A Single-Cell Transcriptomic Atlas of Cytokine Storm in CAR-T Therapy, COVID-19, and SLE

IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies

Targeting Mitophagy Enhances Cytotoxicity of Autologously-Derived CAR-T Cells

Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL

A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

CD19 CAR-T Therapy for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia: A Multicenter Study

Clinical Characteristics and Outcomes of BCMA-Targeted CAR-T Cell Recipients with Coronavirus Disease 2019 during the Omicron Wave: A Retrospective Study

Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma

Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL

CD19/BCMA CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus - Safety and Preliminary Efficacy Data from a Phase I Clinical Study

A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy

A Multicenter Study of CAR-T Cell Therapy for Relapse of B-ALL Post Allogeneic Stem Cell Transplantation

Characteristics of Central Nervous System Relapse after CD19 CAR-T Cell Therapy in R/R NHL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only